These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 8286206)

  • 1. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
    Lissoni P; Barni S; Tancini G; Ardizzoia A; Ricci G; Aldeghi R; Brivio F; Tisi E; Rovelli F; Rescaldani R
    Br J Cancer; 1994 Jan; 69(1):196-9. PubMed ID: 8286206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
    Cerea G; Vaghi M; Ardizzoia A; Villa S; Bucovec R; Mengo S; Gardani G; Tancini G; Lissoni P
    Anticancer Res; 2003; 23(2C):1951-4. PubMed ID: 12820485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer.
    Lissoni P; Meregalli S; Fossati V; Paolorossi F; Barni S; Tancini G; Frigerio F
    Tumori; 1994 Dec; 80(6):464-7. PubMed ID: 7900237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
    Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
    In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
    Lissoni P; Malugani F; Malysheva O; Kozlov V; Laudon M; Conti A; Maestroni G
    Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract.
    Lissoni P; Barni S; Tancini G; Ardizzoia A; Rovelli F; Cazzaniga M; Brivio F; Piperno A; Aldeghi R; Fossati D
    Br J Cancer; 1993 Jun; 67(6):1404-7. PubMed ID: 8512825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin.
    Lissoni P; Barni S; Ardizzoia A; Olivini G; Brivio F; Tisi E; Tancini G; Characiejus D; Kothari L
    J Biol Regul Homeost Agents; 1993; 7(4):121-5. PubMed ID: 8023699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin.
    Lissoni P; Mandalà M; Brivio F
    Eur Urol; 2000 Jul; 38(1):115-8. PubMed ID: 10859453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors.
    Lissoni P; Brivio F; Fumagalli L; Messina G; Vigoré L; Parolini D; Colciago M; Rovelli F
    Anticancer Res; 2008; 28(2B):1377-81. PubMed ID: 18505083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin.
    Lissoni P; Fumagalli L; Paolorossi F; Rovelli F; Roselli MG; Maestroni GJ
    J Biol Regul Homeost Agents; 1997; 11(3):119-22. PubMed ID: 9498162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
    Lissoni P; Brivio F; Brivio O; Fumagalli L; Gramazio F; Rossi M; Emanuelli G; Alderi G; Lavorato F
    J Biol Regul Homeost Agents; 1995; 9(1):31-3. PubMed ID: 8553906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors.
    Lissoni P; Barni S; Tancini G; Mainini E; Piglia F; Maestroni GJ; Lewinski A
    Oncology; 1995; 52(2):163-6. PubMed ID: 7854778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
    Lissoni P; Bolis S; Brivio F; Fumagalli L
    Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of the concomitant administration of the pineal hormone melatonin in cancer immunotherapy with low-dose IL-2 in patients with advanced solid tumors who had progressed on IL-2 alone.
    Lissoni P; Barni S; Cazzaniga M; Ardizzoia A; Rovelli F; Brivio F; Tancini G
    Oncology; 1994; 51(4):344-7. PubMed ID: 8208518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates.
    Barni S; Lissoni P; Cazzaniga M; Ardizzoia A; Meregalli S; Fossati V; Fumagalli L; Brivio F; Tancini G
    Oncology; 1995; 52(3):243-5. PubMed ID: 7715908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms.
    Lissoni P
    Ann N Y Acad Sci; 2000; 917():560-7. PubMed ID: 11268384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients.
    Lissoni P; Barni S; Ardizzoia A; Brivio F; Tancini G; Conti A; Maestroni GJ
    J Biol Regul Homeost Agents; 1992; 6(4):132-6. PubMed ID: 1296454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms.
    Lissoni P
    Pathol Biol (Paris); 2007; 55(3-4):201-4. PubMed ID: 17446010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer.
    Lissoni P; Tisi E; Barni S; Ardizzoia A; Rovelli F; Rescaldani R; Ballabio D; Benenti C; Angeli M; Tancini G
    Br J Cancer; 1992 Jul; 66(1):155-8. PubMed ID: 1322155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms.
    Lissoni P; Giani L; Zerbini S; Trabattoni P; Rovelli F
    Nat Immun; 1998; 16(1):27-33. PubMed ID: 9789122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.